Here are just a few editorial highlights from the DDNews Cancer Research News site and other online vehicles of DDNews magazine to get you acquainted with the website and show you the range of our coverage.

By Dr. Dragan Cicic, Actinium Pharmaceuticals Inc.
Patients with blood cancers often face poor long-term survival outcomes, but a new treatment approach could offer more effective targeting of cancer cells as well as lower toxicity.
By Kelsey Kaustinen, DDNews Senior Editor
If all milestones are met, the agreement could be worth up to $817 million
By Kelsey Kaustinen, DDNews Senior Editor
The effectiveness of anthracyclines, a standard of cancer care, is marred by the associated heart damage they cause; a recent study, however, reports that wrapping the drugs in a fatty cover can minimize cardiotoxicity.
By Lloyd Dunlap, DDNews Managing Editor
Immunomedics Inc. has received notice from the U.S. Food and Drug Administration designating as a Fast Track development program the investigation of sacituzumab govitecan, the company's lead antibody-drug conjugate, for the treatment of patients with triple-negative breast cancer
By Kelsey Kaustinen, DDNews Senior Editor
When the STP axis is expressed, causing low REST protein levels, clinical outcomes in the lab are poor, while inhibition of the axis was found to increase REST levels, which impaired tumor formation and progression.

Ventana, Bayer collaborate on ADC diagnostic test
March 2012

TUSCON, Ariz.—Ventana Medical Systems Inc. and Bayer Pharma AG have joined forces to develop a molecular companion diagnostic test to identify patients that are most likely to benefit from Bayer's antibody-drug conjugate, or ADC, cancer therapy. Per the agreement, Ventana will use its technology to analyze expression levels in certain tumor targets serving as biomarkers in clinical studies and will be responsible for developing, manufacturing and commercializing a test for one of Bayer's ADC drugs. For up to five years, either company can initiate further projects to develop diagnostic tests for additional cancer therapy drugs. Financial terms were not disclosed.
"As new biomarkers and diagnostic tests become increasingly available, they provide valuable information about potential positive recipients for these novel agents," Mara Aspinall, president of Ventana, said in a press release.

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2015 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.